These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 33006723)

  • 1. HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome.
    Gigli GL; Vogrig A; Nilo A; Fabris M; Biasotto A; Curcio F; Miotti V; Tascini C; Valente M
    Neurol Sci; 2020 Dec; 41(12):3391-3394. PubMed ID: 33006723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic.
    Uncini A; Vallat JM; Jacobs BC
    J Neurol Neurosurg Psychiatry; 2020 Oct; 91(10):1105-1110. PubMed ID: 32855289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facial diplegia, a possible atypical variant of Guillain-Barré Syndrome as a rare neurological complication of SARS-CoV-2.
    Juliao Caamaño DS; Alonso Beato R
    J Clin Neurosci; 2020 Jul; 77():230-232. PubMed ID: 32410788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guillain-Barré Syndrome Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Detection and Coronavirus Disease 2019 in a Child.
    Khalifa M; Zakaria F; Ragab Y; Saad A; Bamaga A; Emad Y; Rasker JJ
    J Pediatric Infect Dis Soc; 2020 Sep; 9(4):510-513. PubMed ID: 32652520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Rare Axonal Variant of Guillain-Barré Syndrome as a Neurological Complication of COVID-19 Infection.
    Agha Abbaslou M; Karbasi M; Mozhdehipanah H
    Arch Iran Med; 2020 Oct; 23(10):718-721. PubMed ID: 33107316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guillain Barre syndrome associated with COVID-19 infection: A case report.
    Sedaghat Z; Karimi N
    J Clin Neurosci; 2020 Jun; 76():233-235. PubMed ID: 32312628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute Motor Axonal Neuropathy Related to COVID-19 Infection: A New Diagnostic Overview.
    Petrelli C; Scendoni R; Paglioriti M; Logullo FO
    J Clin Neuromuscul Dis; 2020 Dec; 22(2):120-121. PubMed ID: 33214404
    [No Abstract]   [Full Text] [Related]  

  • 8. Guillain-Barré syndrome associated with leptomeningeal enhancement following SARS-CoV-2 infection.
    Sancho-Saldaña A; Lambea-Gil Á; Liesa JLC; Caballo MRB; Garay MH; Celada DR; Serrano-Ponz M
    Clin Med (Lond); 2020 Jul; 20(4):e93-e94. PubMed ID: 32518103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19-associated Guillain-Barré syndrome: The early pandemic experience.
    Caress JB; Castoro RJ; Simmons Z; Scelsa SN; Lewis RA; Ahlawat A; Narayanaswami P
    Muscle Nerve; 2020 Oct; 62(4):485-491. PubMed ID: 32678460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Facing acute neuromuscular diseases during COVID-19 pandemic: focus on Guillain-Barré syndrome.
    Galassi G; Marchioni A
    Acta Neurol Belg; 2020 Oct; 120(5):1067-1075. PubMed ID: 32696312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease.
    Abrams RMC; Kim BD; Markantone DM; Reilly K; Paniz-Mondolfi AE; Gitman MR; Choo SY; Tse W; Robinson-Papp J
    J Neurovirol; 2020 Oct; 26(5):797-799. PubMed ID: 32720233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Case of Guillain-Barré Syndrome Associated With COVID-19.
    Rajdev K; Victor N; Buckholtz ES; Hariharan P; Saeed MA; Hershberger DM; Bista S
    J Investig Med High Impact Case Rep; 2020; 8():2324709620961198. PubMed ID: 32981333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guillain-Barré syndrome during SARS-CoV-2 pandemic: A case report and review of recent literature.
    Scheidl E; Canseco DD; Hadji-Naumov A; Bereznai B
    J Peripher Nerv Syst; 2020 Jun; 25(2):204-207. PubMed ID: 32388880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain-Barré syndrome.
    Massa F; Vigo T; Bellucci M; Giunti D; Emanuela MM; Visigalli D; Capodivento G; Cerne D; Assini A; Boni S; Rizzi D; Narciso E; Grisanti GS; Coco E; Uccelli A; Schenone A; Franciotta D; Benedetti L
    Neurol Sci; 2024 Mar; 45(3):849-859. PubMed ID: 38169013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guillain-Barré syndrome after covid-19 infection.
    García-Manzanedo S; López de la Oliva Calvo L; Ruiz Álvarez L
    Med Clin (Barc); 2020 Oct; 155(8):366. PubMed ID: 32718718
    [No Abstract]   [Full Text] [Related]  

  • 16. SARS-CoV-2-Associated Guillain-Barre Syndrome With Good Response to Plasmapheresis.
    Granger A; Omari M; Jakubowska-Sadowska K; Boffa M; Zakin E
    J Clin Neuromuscul Dis; 2020 Sep; 22(1):58-59. PubMed ID: 32833726
    [No Abstract]   [Full Text] [Related]  

  • 17. Guillain-Barré syndrome related to COVID-19 infection.
    Alberti P; Beretta S; Piatti M; Karantzoulis A; Piatti ML; Santoro P; Viganò M; Giovannelli G; Pirro F; Montisano DA; Appollonio I; Ferrarese C
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32350026
    [No Abstract]   [Full Text] [Related]  

  • 18. Guillain-Barre syndrome during COVID-19 pandemic: an overview of the reports.
    Rahimi K
    Neurol Sci; 2020 Nov; 41(11):3149-3156. PubMed ID: 32876777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital.
    Ottaviani D; Boso F; Tranquillini E; Gapeni I; Pedrotti G; Cozzio S; Guarrera GM; Giometto B
    Neurol Sci; 2020 Jun; 41(6):1351-1354. PubMed ID: 32399950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guillain-Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing.
    Dalakas MC
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32518172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.